Chemomab Therapeutics (CMMB) Common Equity (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported Common Equity for 10 consecutive years, with $8.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 10.45% year-over-year to $8.7 million; the trailing twelve-month figure through Jun 2026 stood at $8.7 million (down 10.45% YoY), and the FY2025 full-year result was $12.3 million, down 8.89% from the prior year.
• Common Equity declined to $8.7 million in Q2 2026 per CMMB's latest filing, from $10.7 million in the prior quarter.
• Across five years, Common Equity topped out at $57.2 million in Q1 2022 and bottomed at $8.7 million in Q2 2026.
• Historically, Common Equity has averaged $21.7 million across 5 years, with a median of $14.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity advanced 3.76% in 2022, then tumbled 59.57% in 2023.
• Over 5 years, Common Equity stood at $36.2 million in 2022, then plunged by 53.08% to $17.0 million in 2023, then slipped by 20.36% to $13.5 million in 2024, then declined by 8.89% to $12.3 million in 2025, then retreated by 29.58% to $8.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $8.7 million, $10.7 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.